On March 31, 2022 Nirogy Therapeutics, a biopharmaceutical company focused on oncology and Immune diseases, reported that presented at the Cancer Immunotherapy: Decoding the cancer immunity interactome, Keystone Conference that took place from March 21-25, 2022 (Press release, Nirogy Therapeutics, MAR 31, 2022, View Source [SID1234611276]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A poster highlighting pre-clinical data of a small molecule dual inhibitor of lactate transporters demonstrates the potential of immune activation in the TME by differential metabolic reprogramming of various immune cells in the TME on treatment with the compound.
nirogy therapeutics to- present at keystone symposia on cancer immunotherapy decoding the cancer immunity interactome british columbia canada
The conference poster presentation "A dual MCT1 and MCT4 inhibitor blocking lactate transport impacts human immune cell response under conditions mimicking the tumor microenvironment" is available on our website at View Source